NVST insider transaction filings
Envista Holdings Corp — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen NVST transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Keel Paul A — Chief Executive Officer, Director | Grant/award (A): 179,730 @ $0 · Grant/award (A): 159,900 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | Hammes Eric D. — Chief Financial Officer | Grant/award (A): 47,970 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Keel Paul A — Chief Executive Officer, Director | Tax withholding (F): 12,811 @ $23.43 | EDGAR |
| 2026-05-21 | 4 | Pierce James Andrew — Director | Grant/award (A): 9,330 @ $0 | EDGAR |
| 2026-05-21 | 4 | Carruthers Wendy — Director | Grant/award (A): 9,330 @ $0 | EDGAR |
| 2026-05-21 | 4 | Jain Vivek — Director | Grant/award (A): 9,330 @ $0 | EDGAR |
| 2026-05-21 | 4 | Huennekens R Scott — Director | Grant/award (A): 12,585 @ $0 | EDGAR |
| 2026-05-21 | 4 | GALLAHUE KIERAN — Director | Grant/award (A): 9,330 @ $0 | EDGAR |
| 2026-05-21 | 4 | Raskas Daniel — Director | Grant/award (A): 9,330 @ $0 | EDGAR |
| 2026-05-21 | 4 | TSINGOS CHRISTINE A — Director | Grant/award (A): 9,330 @ $0 | EDGAR |
| 2026-02-27 | 4 | Acurio Veronica — President, Orthodontics | Tax withholding (F): 1,412 @ $29.59 · Grant/award (A): 7,605 @ $0 · Grant/award (A): 13,845 (derivative) @ $0 · Grant/award (A): 18,020 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Nilsson Stefan — President, Nobel Biocare | Tax withholding (F): 182 @ $29.59 · Grant/award (A): 7,605 @ $0 · Grant/award (A): 13,845 (derivative) @ $0 · Grant/award (A): 18,020 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Befidi Robert — President, Diagnostics | Tax withholding (F): 2,177 @ $29.59 · Grant/award (A): 7,605 @ $0 · Grant/award (A): 13,845 (derivative) @ $0 · Grant/award (A): 18,020 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Kaabi Faez C — Chief Accounting Officer | Tax withholding (F): 4,964 @ $29.59 · Grant/award (A): 13,520 @ $0 | EDGAR |
| 2026-02-27 | 4 | Reis Mischa — SVP, Strategy & Bus. Dev. | Tax withholding (F): 2,976 @ $29.59 · Grant/award (A): 5,915 @ $0 · Grant/award (A): 10,770 (derivative) @ $0 · Grant/award (A): 14,020 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Nance Mark E — General Counsel | Tax withholding (F): 3,368 @ $29.59 · Grant/award (A): 12,675 @ $0 · Grant/award (A): 23,070 (derivative) @ $0 · Grant/award (A): 30,040 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Keel Paul A — Chief Executive Officer, Director | Tax withholding (F): 11,840 @ $29.59 · Grant/award (A): 48,670 @ $0 · Grant/award (A): 132,885 (derivative) @ $0 · Grant/award (A): 115,320 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Hammes Eric D. — Chief Financial Officer | Tax withholding (F): 2,045 @ $29.59 · Grant/award (A): 16,055 @ $0 · Grant/award (A): 29,225 (derivative) @ $0 · Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Reis Mischa — SVP, Strategy & Bus. Dev. | Option exercise (M): 4,041 @ $19.04 · Sale (S): 4,041 @ $30 · Option exercise (M): 5,634 @ $15.97 · Sale (S): 5,634 @ $30 · Option exercise (M): 4,041 (derivative) @ $0 · Option exercise (M): 5,634 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Acurio Veronica — President, Orthodontics | Grant/award (A): 998 (derivative) @ $23.47 | EDGAR |
| 2026-02-03 | 4 | Befidi Robert — President, Diagnostics | Grant/award (A): 998 (derivative) @ $23.47 | EDGAR |
| 2026-02-03 | 4 | Kaabi Faez C — Chief Accounting Officer | Grant/award (A): 1,186 (derivative) @ $23.47 | EDGAR |
| 2026-02-03 | 4 | Reis Mischa — SVP, Strategy & Bus. Dev. | Grant/award (A): 2,919 (derivative) @ $21.71 | EDGAR |
| 2026-02-03 | 4 | Nance Mark E — General Counsel | Grant/award (A): 2,006 (derivative) @ $23.47 | EDGAR |
| 2026-02-03 | 4 | Keel Paul A — Chief Executive Officer, Director | Grant/award (A): 4,091 (derivative) @ $23.47 | EDGAR |
| 2026-02-03 | 4 | Hammes Eric D. — Chief Financial Officer | Grant/award (A): 1,119 (derivative) @ $23.47 | EDGAR |
| 2025-11-04 | 4 | Keel Paul A — Chief Executive Officer, Director | Tax withholding (F): 54,097 @ $20.35 | EDGAR |
| 2025-08-27 | 4 | Acurio Veronica — President, Orthodontics | Tax withholding (F): 5,422 @ $21.12 | EDGAR |
| 2025-08-27 | 4 | Nilsson Stefan — President, Nobel Biocare | Tax withholding (F): 804 @ $21.12 | EDGAR |
| 2025-08-27 | 4 | Befidi Robert — President, Diagnostics | Tax withholding (F): 3,454 @ $21.12 | EDGAR |
| 2025-08-27 | 4 | Reis Mischa — SVP, Strategy & Bus. Dev. | Sale (S): 15,000 @ $21.60 | EDGAR |
| 2025-08-27 | 4 | Hammes Eric D. — Chief Financial Officer | Tax withholding (F): 7,654 @ $21.12 | EDGAR |
| 2025-07-16 | 4 | Pierce James Andrew — Director | Grant/award (A): 9,155 @ $0 | EDGAR |
| 2025-06-12 | 4 | Hulit Barbara B. — Director | Grant/award (A): 10,450 @ $0 | EDGAR |
| 2025-06-12 | 4 | Carruthers Wendy — Director | Grant/award (A): 10,450 @ $0 | EDGAR |
| 2025-06-12 | 4 | Jain Vivek — Director | Grant/award (A): 10,450 @ $0 | EDGAR |
| 2025-06-12 | 4 | Huennekens R Scott — Director | Grant/award (A): 14,370 @ $0 | EDGAR |
| 2025-06-12 | 4 | GALLAHUE KIERAN — Director | Grant/award (A): 10,450 @ $0 | EDGAR |
| 2025-06-12 | 4 | Raskas Daniel — Director | Grant/award (A): 10,450 @ $0 | EDGAR |
| 2025-06-12 | 4 | TSINGOS CHRISTINE A — Director | Grant/award (A): 10,450 @ $0 | EDGAR |
| 2025-05-27 | 4 | Keel Paul A — Chief Executive Officer, Director | Tax withholding (F): 12,787 @ $16.72 | EDGAR |
| 2025-02-27 | 4 | Kaabi Faez C — Chief Accounting Officer | Tax withholding (F): 4,319 @ $20.66 · Grant/award (A): 9,685 @ $0 · Grant/award (A): 22,600 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Reis Mischa — SVP, Strategy & Bus. Dev. | Tax withholding (F): 3,813 @ $20.66 · Grant/award (A): 8,475 @ $0 · Grant/award (A): 15,615 (derivative) @ $0 · Grant/award (A): 19,780 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Acurio Veronica — President, Orthodontics | Grant/award (A): 10,290 @ $0 · Grant/award (A): 18,960 (derivative) @ $0 · Grant/award (A): 24,010 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Nilsson Stefan — President, Nobel Biocare | Grant/award (A): 10,290 @ $0 · Grant/award (A): 18,960 (derivative) @ $0 · Grant/award (A): 24,010 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Befidi Robert — President, Diagnostics | Tax withholding (F): 1,123 @ $20.66 · Grant/award (A): 10,290 @ $0 · Grant/award (A): 18,960 (derivative) @ $0 · Grant/award (A): 24,010 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Nance Mark E — General Counsel | Tax withholding (F): 3,691 @ $20.66 · Grant/award (A): 18,155 @ $0 · Grant/award (A): 33,455 (derivative) @ $0 · Grant/award (A): 42,370 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Keel Paul A — Chief Executive Officer, Director | Grant/award (A): 65,830 @ $0 · Grant/award (A): 181,985 (derivative) @ $0 · Grant/award (A): 153,660 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Hammes Eric D. — Chief Financial Officer | Grant/award (A): 15,735 @ $0 · Grant/award (A): 28,995 (derivative) @ $0 · Grant/award (A): 36,720 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Befidi Robert — President, Diagnostics | Grant/award (A): 1,151 (derivative) @ $20.52 | EDGAR |
Recent 8-K events — Envista Holdings Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-29 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-31 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NVST returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →